GLPwatch
Papers (9189)
Page 76 of 154, ranked by citation count.
- The effect of subcutaneous dulaglutide on weight loss in patients with Type 2 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
- Exenatide Regulates Substrate Preferences Through the p38γ MAPK Pathway After Ischaemia/Reperfusion Injury in a Rat Heart.
- Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme.
- Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice.
- One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes.
- GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment.
- Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
- Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
- Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease.
- Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus.
- Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.
- Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
- The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan.
- GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice.
- Semaglutide for weight loss: unanswered questions.
- Semaglutide for obesity: four STEPs forward, but more to come.
- Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes.
- Tirzepatide and potential use for metabolically healthy obesity.
- Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.
- The impact of approved anti-obesity medications on osteoarthritis.
- Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
- Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function.
- Long-Term Liraglutide Administration Induces Pancreas Neogenesis in Adult T2DM Mice.
- Intelligent Escape System for the Oral Delivery of Liraglutide: A Perfect Match for Gastrointestinal Barriers.
- Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction.
- An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks.
- Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study.
- Exendin-4 regulates GLUT2 expression via the CaMKK/CaMKIV pathway in a pancreatic β-cell line.
- PDGF Facilitates Direct Lineage Reprogramming of Hepatocytes to Functional β-Like Cells Induced by Pdx1 and Ngn3.
- IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience.
- Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.
- The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
- Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis.
- Cardiovascular disease leads to a new algorithm for diabetes treatment.
- Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review.
- Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.
- Potential contributors to variation in weight-loss response to liraglutide.
- Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
- Liraglutide: effects beyond glycaemic control in diabetes treatment.
- Repression of sterol regulatory element-binding protein 1-c is involved in the protective effects of exendin-4 in pancreatic β-cell line.
- A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.
- Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.
- Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
- Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients.
- Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms.
- Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice.
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders.
- Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity.
- Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.
- Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
- Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States.
- An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice.
- Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.
- Current pharmacotherapies for obesity: A practical perspective.
- Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.
- Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
- Semaglutide for Weight Loss: Was It Worth the Weight?
- Liraglutide regulates the viability of pancreatic α-cells and pancreatic β-cells through cAMP-PKA signal pathway.
- Overview of new antiobesity drugs.
- Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus.